NIH holds the patent for targeting Janus kinases and discovering novel immunosuppressive agents. It has now been 20 years since the discovery of the Jak/STAT pathway. This pathway has become a paradigm in signal transduction, but has also shed light on a number of diseases ranging from immunodeficiencies to hematological malignancies. Importantly, many pharmaceutical firms have targeted Janus kinases as a new class of immunomodulatory drugs. This meeting focussed on the translational advances that have arisen with the basic discoveries of this important Jak/STAT pathway.

Sponsors